Cytokine Storm Drugs Move from CAR T to COVID-19 #MMPMID32371479
ä
Cancer Discov 2020[Jul]; 10 (7): OF8 PMID32371479show ga
Early reports suggest that tocilizumab, an IL6 receptor-blocking antibody used to manage toxicities associated with chimeric antigen receptor T-cell therapy, may help control cytokine storms in people infected with COVID-19. Preliminary data from randomized trials are less clear-cut.